-----------------------------------------------------------------------------


                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


        Date of Report (Date of earliest event reported): April 29, 2005




                                 OCCULOGIX, INC.
             (Exact name of Registrant as specified in its Charter)


         Delaware                    000 51030           59-343-4771
(State or other Jurisdiction)       (Commission         (IRS Employer
     of Incorporation)              File Number)      Identification No.)


                     2600 Skymark Avenue, Unit 9, Suite 201
                          Mississauga, Ontario L4W 5B2
                    (Address of principal executive offices)


       Registrant's telephone number, including area code: (905) 602-0887

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

|_|   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))

  ----------------------------------------------------------------------------

<PAGE>

ITEM 5.02 Election of Directors

On May 2, 2005, the Company issued a press release announcing that Adrienne L.
Graves, Ph.D. had been appointed to the Board of Directors of the Company by the
current directors. Dr. Graves is not expected to be named to any committees of
the Board of Directors at this time.

ITEM 9.01 Financial Statements and Exhibits

(c) Exhibits

99.1  Press Release of OccuLogix, Inc. dated May 2, 2005.

<PAGE>

                                     - 3 -

                                    SIGNATURE

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
Company has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                           OCCULOGIX, INC.

Date:  May 4, 2005
                                            By: /s/ Elias Vamvakas
                                                ---------------------------
                                                    Elias Vamvakas
                                                    Chief Executive Officer
{"company-data": {"conformed-name": "OccuLogix, Inc.", "cik": "0001299139", "assigned-sic": "3841", "irs-number": "593434771", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-51030", "film-number": "05797503"}, "business-address": {"street1": "5280 SOLAR DRIVE, SUITE 100", "city": "MISSISSAUGA", "state": "A6", "zip": "L4W 5M8", "phone": "905-602-2020"}, "mail-address": {"street1": "5280 SOLAR DRIVE, SUITE 100", "city": "MISSISSAUGA", "state": "A6", "zip": "L4W 5M8"}}
-----------------------------------------------------------------------------

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

        Date of Report (Date of earliest event reported): April 29, 2005

                                 OCCULOGIX, INC.
             (Exact name of Registrant as specified in its Charter)

         Delaware                    000 51030           59-343-4771
(State or other Jurisdiction)       (Commission         (IRS Employer
     of Incorporation)              File Number)      Identification No.)

                     2600 Skymark Avenue, Unit 9, Suite 201
                          Mississauga, Ontario L4W 5B2
                    (Address of principal executive offices)

       Registrant's telephone number, including area code: (905) 602-0887

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

|_|   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))

  ----------------------------------------------------------------------------
ITEM 5.02 Election of Directors

On May 2, 2005, the Company issued a press release announcing that Adrienne L.
Graves, Ph.D. had been appointed to the Board of Directors of the Company by the
current directors. Dr. Graves is not expected to be named to any committees of
the Board of Directors at this time.

ITEM 9.01 Financial Statements and Exhibits

(c) Exhibits

99.1  Press Release of OccuLogix, Inc. dated May 2, 2005.
- 3 -

                                    SIGNATURE

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
Company has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                           OCCULOGIX, INC.

Date:  May 4, 2005
                                            By: /s/ Elias Vamvakas
                                                ---------------------------
                                                    Elias Vamvakas
                                                    Chief Executive Officer